IPA to Report Money Benefits and The latest Organization Highlights for 2nd Quarter Fiscal Calendar year 2023 on December 15, 2022

The Firm to host an earnings conference simply call by using webcast

VICTORIA, British Columbia, December 05, 2022–(Enterprise WIRE)–IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Enterprise” or “IPA”) (NASDAQ: IPA), an sophisticated biotherapeutic exploration and technology corporation, currently introduced that it will host a meeting get in touch with to discuss its quarterly benefits and current enterprise highlights for 2nd quarter fiscal year 2023, on Thursday, December 15, 2022, at 10:30 am Eastern Time. The monetary effects will be issued in a press release prior to the phone.

ImmunoPrecise management will host the meeting call followed by a question-and-answer interval.

Conference Call:

Date: Thursday, December 15, 2022
Time: 10:30 am Japanese time

Participant Info:

Convention ID: 9236374
Participant Toll-Free Dial-In Variety: 1 (888) 550-5658
Participant Toll Dial-In Quantity: 1 (646) 960-0289

Attendee URL: https://gatherings.q4inc.com/attendee/662019205

The convention contact will be webcast dwell and obtainable for replay by using a link delivered in the Situations portion of the company’s IR web pages at https://www.immunoprecise.com/traders.

Please connect with the meeting telephone amount five minutes prior to the begin time. An operator will sign-up your title and firm.

Any one listening to the phone is inspired to browse the firm’s periodic reviews on file with the Toronto Stock Trade and Securities and Trade Fee, which includes the discussion of possibility things and historic success of operations and economic situation in individuals stories.

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. has quite a few subsidiaries in North The us and Europe like entities this kind of as Talem Therapeutics LLC, Biostrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family members”). The IPA Relatives is a biotherapeutic research and engineering group that leverages systems biology, multi-omics modelling and intricate artificial intelligence systems to assistance its proprietary technologies in bioplatform-based mostly antibody discovery. Solutions contain hugely specialised, comprehensive-continuum therapeutic biologics discovery, growth, and out-licensing to support its business enterprise companions in their quest to learn and build novel biologics against the most complicated targets. For more data, stop by www.ipatherapeutics.com.

Tale continues

See supply version on businesswire.com: https://www.businesswire.com/information/residence/20221205005242/en/


Trader contact: traders@immunoprecise.com

Information Viber